December 15th, 2015

Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Biogen to Develop Blood Medicines in Deal With Sangamo

[at Bloomberg] – Biogen Idec Inc., the maker of drugs for multiple sclerosis and hemophilia, agreed to pay as much as $320 million to develop medicines for blood disorders with Sangamo BioSciences Inc. . . . → Read More: Company Update: Biogen Idec Inc. (NASDAQ:BIIB) – Biogen to Develop Blood Medicines in Deal With Sangamo

Biogen Idec Inc. (NASDAQ:BIIB) [at Bloomberg] – Biogen Idec Inc., the maker of drugs for multiple sclerosis and hemophilia, agreed to pay as much as $320 million to develop medicines for blood disorders with Sangamo BioSciences Inc.
Read more on this.

… [visit site to read more]

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.